Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMM 40H

Next Previous
X
Search
Drug Profile

IMM 40H

Alternative Names: IMM-40H

Latest Information Update: 20 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuneOnco Biopharma
  • Class Antineoplastics; Immunoglobulins; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD70 antigen modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 20 Jul 2023 The US FDA accepts IND application of IMM 40H for Haematological malignancies and Solid tumours for review (ImmuneOnco Biopharma pipeline, July 2023)
  • 22 Sep 2022 ImmuneOnco Biopharmaceuticals plans a phase I trial for Solid tumor and Hematological malignancies (In adults, In the elderly, Late stage disease, Second line therapy or greater)(Parenteral)(NCT05549557)
  • 12 Sep 2022 ImmuneOnco Biopharma announces intention to submit IND to the US FDA for Haematological malignancies and Solid tumours, in Q3 of 2022 (ImmuneOnco Biopharma pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top